These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 370159)
1. Postmarketing surveillance of new drugs: I. Review of objectives and methodology. Wardell WM; Tsianco MC; Anavekar SN; Davis HT J Clin Pharmacol; 1979; 19(2-3):85-94. PubMed ID: 370159 [No Abstract] [Full Text] [Related]
2. Discovering adverse drug reactions. Lasagna L JAMA; 1983 Apr 22-29; 249(16):2224-5. PubMed ID: 6339764 [No Abstract] [Full Text] [Related]
3. Post-marketing surveillance of prescription drug safety: past, present, and future. Chen BK; Yang YT J Leg Med; 2013; 34(2):193-213. PubMed ID: 23980746 [No Abstract] [Full Text] [Related]
4. Can postmarketing surveillance help to effect optimal drug therapy? Strom BL; Melmon KL JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922 [TBL] [Abstract][Full Text] [Related]
5. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012. Cheng CM; Shin J; Guglielmo BJ JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107 [No Abstract] [Full Text] [Related]
6. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications: introduction. Shane R Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S2-3. PubMed ID: 19966076 [No Abstract] [Full Text] [Related]
7. Assessing Drug Safety in Children - The Role of Real-World Data. McMahon AW; Dal Pan G N Engl J Med; 2018 Jun; 378(23):2155-2157. PubMed ID: 29874532 [No Abstract] [Full Text] [Related]
8. Postmarketing surveillance of new drugs: II. Case studies. Wardell WM; Tsianco MC; Anavekar SN; Davis HT J Clin Pharmacol; 1979 Apr; 19(4):169-84. PubMed ID: 374427 [No Abstract] [Full Text] [Related]
9. Legal perspectives in causality assessment. Freilich WB Drug Inf J; 1984; 18(3-4):211-7. PubMed ID: 10268552 [TBL] [Abstract][Full Text] [Related]
10. A prescription for monitoring drugs. Marshall E Science; 1980 Feb; 207(4433):853-5. PubMed ID: 7355265 [No Abstract] [Full Text] [Related]
11. Immortality for old drugs? Herxheimer A Lancet; 1984 Jun; 1(8392):1460-1. PubMed ID: 6145891 [No Abstract] [Full Text] [Related]
12. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457 [TBL] [Abstract][Full Text] [Related]
13. The QAU: friend, not foe. Sewell AF; Spencer CD J Clin Pharmacol; 1991 Jun; 31(6):509-11. PubMed ID: 1880214 [No Abstract] [Full Text] [Related]
14. Drug dangers and reactions. WEILERSTEIN RW Calif Med; 1961 Jan; 94(1):9-11. PubMed ID: 13783849 [TBL] [Abstract][Full Text] [Related]
15. Post-marketing surveillance in the UK (1984). Lawson DH Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):71S-75S. PubMed ID: 3567035 [No Abstract] [Full Text] [Related]
16. Drug safety, pharmacoepidemiology, and regulatory decision making. Nelson RC Drug Intell Clin Pharm; 1988 Apr; 22(4):336-44. PubMed ID: 3371198 [TBL] [Abstract][Full Text] [Related]
18. The medical-legal aspects of adverse drug reactions. Tozer FL; Kasik JE Clin Pharmacol Ther; 1967; 8(5):637-46. PubMed ID: 6072449 [No Abstract] [Full Text] [Related]
19. Sounding board. Unapproved drugs in the practice of medicine. Franklin W; Lowell FC N Engl J Med; 1975 May; 292(20):1075-7. PubMed ID: 1124091 [No Abstract] [Full Text] [Related]